Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 19,109 Shares

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) insider Terrie Curran sold 19,109 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $125,928.31. Following the completion of the transaction, the insider now owns 360,465 shares in the company, valued at $2,375,464.35. This represents a 5.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Phathom Pharmaceuticals Trading Up 2.6 %

Shares of PHAT stock traded up $0.18 during trading hours on Thursday, reaching $7.17. The company’s stock had a trading volume of 649,135 shares, compared to its average volume of 943,045. The stock has a market capitalization of $490.28 million, a P/E ratio of -1.26 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a one year low of $6.07 and a one year high of $19.71. The firm’s fifty day simple moving average is $8.08 and its 200 day simple moving average is $12.53.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.57) by $0.25. The business had revenue of $16.35 million during the quarter, compared to the consensus estimate of $12.54 million. During the same quarter in the prior year, the business posted ($0.76) earnings per share. As a group, equities research analysts forecast that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Kera Capital Partners Inc. purchased a new position in Phathom Pharmaceuticals during the fourth quarter valued at $218,000. Barclays PLC raised its stake in shares of Phathom Pharmaceuticals by 366.0% in the third quarter. Barclays PLC now owns 57,807 shares of the company’s stock worth $1,044,000 after purchasing an additional 45,402 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Phathom Pharmaceuticals by 7.1% in the third quarter. Geode Capital Management LLC now owns 862,918 shares of the company’s stock worth $15,605,000 after purchasing an additional 56,871 shares during the last quarter. MML Investors Services LLC raised its stake in shares of Phathom Pharmaceuticals by 72.8% in the third quarter. MML Investors Services LLC now owns 33,860 shares of the company’s stock worth $612,000 after purchasing an additional 14,260 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Phathom Pharmaceuticals by 17.5% in the third quarter. State Street Corp now owns 922,788 shares of the company’s stock worth $16,684,000 after purchasing an additional 137,539 shares during the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Analyst Ratings Changes

PHAT has been the topic of several recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.